News: WADA Symposium Covers Broad Spectrum of Gene Doping, and Potential for Misuse of Cell Therapy in World of Sport
|
Leading experts in gene therapy, scientists from the field of anti-doping, and sport ethicists joined WADA’s Gene Doping Panel at the Agency’s Fourth Gene and Cell Doping Symposium, held June 5-6 in Beijing to review recent achievements in the field and share the most promising approaches in doping detection under development. Organized with the support of the China Anti-Doping Agency (CHINADA) and Beijing Olympic City Development Association (BODA), the Symposium attracted more than 70 international participants. Sixteen invited speakers included international experts who either study the latest advances in the field of gene therapy and gene doping detection methods, or are involved in related WADA-funded research projects. The 2013 Symposium was the first to dedicate a formal session to cell therapy and doping.
Read more... |
News: Public consultation on advanced therapy medicinal products: A summary of the responses
|
The European Commission should prepare a report on the application of Regulation (EC) No 1394/2007 on advanced therapy medicinal products. With a view to prepare this report, the Commission services launched a public consultation on 20 December 2012. Stakeholders were invited to provide their views on the requirements to obtain a marketing authorisation for an ATMP (including for combined ATMPs), on the application of the so-called hospital exemption, on the incentives provided for in the ATMP Regulation, as well as on the scope thereof and its adaptation to technical progress. The number of contributions received was 63.
Read more... |
News: Scientists reveal inside story of European regulatory review and approval of Glybera
|
The scientists who led the team that developed Glybera, the first gene therapy drug approved for use in the Western world, provide a fascinating first-person account of their pioneering work in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. In addition, an in-depth Review revealing the inside story of the European regulatory review and approval of Glybera—chock full of twists and turns, politics, and intrigue— and critiquing the groundbreaking drug's path to the marketplace appears in Human Gene Therapy Clinical Development. Both articles are available free on the Human Gene Therapy website.
Read more... |
Conferences
|
- |
15 – 18 June 2013, The Seventh International Meeting on Replicating Oncolytic Virus Therapeutics, Quebec, Canada |
- |
4 – 6 July 2013, The 19th Annual Meeting of the Japan Society of Gene Therapy (JSGT), Okayama, Japan |
- |
12 – 14 August 2013, International Conference on Genetic Engineering & Genetically Modified Organisms, Raleigh, North Carolina |
- |
30 September – 1 October 2013, Stem Cells & Regenerative Medicine Congress, Cambridge, MA |
- |
30 September – 1 October 2013, Cell Culture World Congress USA, Cambridge, MA |
- |
30 September – 1 October 2013, World Cord Blood Congress, Cambridge, MA |
- |
23 – 25 October 2013, 2nd
International Conference and Exhibition on Cell & Gene Therapy, Orlanda, Florida |
- |
24 – 28 October 2013, VII Congress of the Spanish Society of Gene (SETGyC) and Cell Therapy, and XXI Congress of the European Society of Gene and Cell Therapy (ESGCT), Madrid, Spain |
- |
4 – 5 November 2013, Stem Cell Congress 2013, London, UK |
- |
20 – 22 November 2013, 12th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases, Sonoma, California |
- |
28 March 2014, Annual conference of the British Society for Gene Therapy (BSGT), London, UK |
- |
21 – 24 May 2014, American Society of Gene and Cell Therapy (ASGCT) 17th Annual Meeting, Washington, DC |
- |
23 – 26 October 2014, XXII Congress of the European Society of Gene and Cell Therapy (ESGCT), The Hague, The Netherlands |
Read more... |
|
|